Evaluating Immunome: Insights From 4 Financial Analysts
Evaluating Immunome: Insights From 4 Financial Analysts
评估免疫组：来自4位金融分析师的见解
In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，有4位分析师发布了Immunome（纳斯达克股票代码：IMNM）的评级，提出了从看涨到看跌的各种观点。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要概述了他们最近的评级，重点介绍了过去30天中情绪的变化，并将其与前几个月进行了比较。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.75, a high estimate of $35.00, and a low estimate of $24.00. This current average reflects an increase of 10.19% from the previous average price target of $27.00.
分析师12个月目标股价的见解已经公布，平均目标股价为29.75美元，最高估计为35.00美元，低估值为24.00美元。目前的平均价格比之前的平均目标价27.00美元增长了10.19％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析师评级：全面细分
A comprehensive examination of how financial experts perceive Immunome...
对金融专家如何看待...
登录免费看全文
登录/注册